PDF DatasheetHuman Anti-Interferon gamma Antibody Product Attributes
Interferon gamma Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Interferon gamma antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of Interferon gamma could be seen inadipocytes in mesenchymal tissue, cells in the endometrial stroma in endometrium, cells in the glomeruli in kidney, cells in the tubules in kidney, fibroblasts in skin, glandular cells in the adrenal gland, appendix, cervix, uterine, duodenum, epididymis, gallbladder, parathyroid gland, rectum, seminal vesicle, small intestine and stomach, keratinocytes in skin, Langerhans in skin, Leydig cells in the testis, macrophages in lung, melanocytes in skin, myocytes in heart muscle and skeletal muscle, neuronal cells in the hippocampus, non-germinal center cells in the tonsil, pneumocytes in lung, respiratory epithelial cells in the nasopharynx, smooth muscle cells in the smooth muscle, squamous epithelial cells in the oral mucosa and urothelial cells in the urinary bladder. We were unable to detect Interferon gamma in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Interferon gamma expression as measured by anti-Interferon gamma antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – |
| IFNG Variability | ++ | ++ | + | ++ | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | + | + | ++ | + |
| Interferon gamma General Information | |
|---|---|
| Alternate Names | |
| Interferon gamma, IFNgamma, IFN gamma, IFN?, IFN-?, IFNg | |
| Molecular Weight | |
| 20-25kDa | |
| Chromosomal Location | |
| 12q14 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | IFNG |
| Entrez Gene ID | 3458 |
| Ensemble Gene ID | ENSG00000111537 |
| RefSeq Protein Accession(s) | NP_000610 |
| RefSeq mRNA Accession(s) | NM_000619 |
| RefSeq Genomic Accession(s) | NG_015840, NC_018923, NC_000012 |
| UniProt ID(s) | P01579 |
| UniGene ID(s) | P01579 |
| HGNC ID(s) | 5438 |
| Cosmic ID(s) | IFNG |
| KEGG Gene ID(s) | hsa:3458 |
| PharmGKB ID(s) | PA29674 |
| General Description of Interferon gamma. | |
| Recognizes a protein of 20-25kDa, identified as human interferon. This MAb is specific to human IFN-? and recognizes both recombinant and native human IFN-gamma. T lymphocytes and NK cells mainly produce IFN-?. It is a pleiotropic cytokine involved in the regulation of nearly all phases of immune and inflammatory responses, including the activation, growth and differentiation of T cell, B cells, macrophages, NK cells and other cell types such as endothelial cells and fibroblasts. It has weak anti-viral and anti-proliferative activity, and potentiates the antiviral and anti-tumor effects of IFN-??? (type I interferon). | |
There are no reviews yet.